| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 182 | 2025 | 3459 | 15.720 |
Why?
|
| Brain Neoplasms | 244 | 2025 | 9071 | 11.510 |
Why?
|
| Glioma | 104 | 2025 | 3493 | 7.770 |
Why?
|
| Dacarbazine | 50 | 2023 | 552 | 4.780 |
Why?
|
| Neoplasm Recurrence, Local | 90 | 2025 | 9373 | 4.550 |
Why?
|
| Angiogenesis Inhibitors | 38 | 2020 | 2056 | 3.780 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 80 | 2022 | 11868 | 3.220 |
Why?
|
| Immunotherapy | 41 | 2025 | 4752 | 2.980 |
Why?
|
| Central Nervous System Neoplasms | 17 | 2025 | 916 | 2.850 |
Why?
|
| Antineoplastic Agents | 55 | 2023 | 13648 | 2.610 |
Why?
|
| Cancer Vaccines | 19 | 2024 | 1044 | 2.530 |
Why?
|
| Astrocytoma | 17 | 2015 | 772 | 1.870 |
Why?
|
| Antineoplastic Agents, Alkylating | 27 | 2024 | 614 | 1.740 |
Why?
|
| Antibodies, Monoclonal | 35 | 2022 | 9249 | 1.680 |
Why?
|
| Meningioma | 15 | 2022 | 1221 | 1.660 |
Why?
|
| Snake Venoms | 6 | 2015 | 40 | 1.650 |
Why?
|
| Meningeal Neoplasms | 16 | 2022 | 1252 | 1.550 |
Why?
|
| Camptothecin | 17 | 2015 | 600 | 1.420 |
Why?
|
| Oligodendroglioma | 13 | 2020 | 273 | 1.420 |
Why?
|
| DNA Modification Methylases | 11 | 2023 | 207 | 1.370 |
Why?
|
| DNA Repair Enzymes | 12 | 2023 | 342 | 1.330 |
Why?
|
| Isocitrate Dehydrogenase | 15 | 2025 | 954 | 1.310 |
Why?
|
| Quinazolines | 14 | 2015 | 1364 | 1.300 |
Why?
|
| Blood-Brain Barrier | 7 | 2024 | 1037 | 1.190 |
Why?
|
| Tenascin | 7 | 2008 | 61 | 1.160 |
Why?
|
| Combined Modality Therapy | 39 | 2025 | 8529 | 1.140 |
Why?
|
| Maximum Tolerated Dose | 25 | 2019 | 898 | 1.110 |
Why?
|
| Dexamethasone | 6 | 2022 | 1963 | 1.060 |
Why?
|
| Radioimmunotherapy | 9 | 2008 | 93 | 1.060 |
Why?
|
| Disease-Free Survival | 43 | 2023 | 6832 | 1.040 |
Why?
|
| Clinical Trials as Topic | 31 | 2022 | 8041 | 1.030 |
Why?
|
| Salvage Therapy | 13 | 2018 | 1272 | 1.010 |
Why?
|
| Nervous System Neoplasms | 2 | 2015 | 91 | 0.980 |
Why?
|
| Humans | 379 | 2025 | 765968 | 0.960 |
Why?
|
| Treatment Outcome | 88 | 2025 | 65188 | 0.940 |
Why?
|
| Sirolimus | 6 | 2012 | 1545 | 0.880 |
Why?
|
| Oncolytic Viruses | 5 | 2023 | 344 | 0.860 |
Why?
|
| Immunoconjugates | 6 | 2019 | 981 | 0.860 |
Why?
|
| Adult | 179 | 2025 | 223044 | 0.840 |
Why?
|
| Medical Oncology | 7 | 2025 | 2339 | 0.830 |
Why?
|
| Middle Aged | 184 | 2025 | 223009 | 0.830 |
Why?
|
| Sonication | 2 | 2020 | 78 | 0.820 |
Why?
|
| Immunomodulation | 2 | 2017 | 547 | 0.800 |
Why?
|
| Tumor Suppressor Proteins | 12 | 2023 | 2796 | 0.800 |
Why?
|
| Aged | 144 | 2025 | 171117 | 0.790 |
Why?
|
| Neovascularization, Pathologic | 9 | 2017 | 2631 | 0.760 |
Why?
|
| Brain Edema | 3 | 2020 | 602 | 0.760 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 6 | 2013 | 660 | 0.750 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 2019 | 3513 | 0.740 |
Why?
|
| Survival Rate | 44 | 2025 | 12795 | 0.740 |
Why?
|
| Indoles | 5 | 2020 | 1839 | 0.740 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2023 | 5696 | 0.730 |
Why?
|
| Carboplatin | 6 | 2019 | 789 | 0.730 |
Why?
|
| Magnetic Resonance Imaging | 52 | 2025 | 36532 | 0.720 |
Why?
|
| Succinimides | 1 | 2020 | 83 | 0.690 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2020 | 70 | 0.690 |
Why?
|
| Male | 199 | 2025 | 363698 | 0.680 |
Why?
|
| Hydroxyurea | 7 | 2012 | 284 | 0.680 |
Why?
|
| Integrins | 5 | 2012 | 840 | 0.670 |
Why?
|
| Female | 206 | 2025 | 396112 | 0.670 |
Why?
|
| Tumor Microenvironment | 15 | 2024 | 3946 | 0.670 |
Why?
|
| Prognosis | 52 | 2025 | 29922 | 0.670 |
Why?
|
| Antigens, Neoplasm | 9 | 2024 | 2002 | 0.650 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 120 | 0.640 |
Why?
|
| Antigen Presentation | 2 | 2023 | 1250 | 0.630 |
Why?
|
| Kaplan-Meier Estimate | 22 | 2020 | 6499 | 0.590 |
Why?
|
| Neurology | 2 | 2015 | 785 | 0.570 |
Why?
|
| Angiopoietins | 1 | 2017 | 86 | 0.570 |
Why?
|
| Pyrimidines | 10 | 2013 | 3047 | 0.560 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2011 | 679 | 0.530 |
Why?
|
| Brain Stem Neoplasms | 3 | 2016 | 192 | 0.530 |
Why?
|
| Microbubbles | 3 | 2024 | 136 | 0.520 |
Why?
|
| Vaccines, Subunit | 7 | 2022 | 158 | 0.510 |
Why?
|
| Drug Delivery Systems | 10 | 2024 | 2207 | 0.500 |
Why?
|
| Melanoma | 7 | 2023 | 5719 | 0.490 |
Why?
|
| Oncolytic Virotherapy | 5 | 2023 | 520 | 0.480 |
Why?
|
| Drug Administration Schedule | 18 | 2015 | 4850 | 0.480 |
Why?
|
| Pituitary Neoplasms | 6 | 2023 | 1321 | 0.480 |
Why?
|
| Iodine Radioisotopes | 4 | 2008 | 1029 | 0.470 |
Why?
|
| Oligopeptides | 2 | 2011 | 1192 | 0.450 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2015 | 1776 | 0.440 |
Why?
|
| Herpesvirus 1, Human | 5 | 2023 | 743 | 0.440 |
Why?
|
| Survival Analysis | 32 | 2023 | 10070 | 0.440 |
Why?
|
| Disease Progression | 31 | 2023 | 13632 | 0.430 |
Why?
|
| Pyridines | 8 | 2018 | 2888 | 0.430 |
Why?
|
| Neoplasms | 15 | 2021 | 22340 | 0.430 |
Why?
|
| Purines | 3 | 2012 | 615 | 0.420 |
Why?
|
| Encephalitis | 1 | 2017 | 441 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2019 | 548 | 0.420 |
Why?
|
| Etoposide | 4 | 2010 | 636 | 0.410 |
Why?
|
| Dendritic Cells | 5 | 2022 | 2747 | 0.410 |
Why?
|
| Molecular Targeted Therapy | 4 | 2019 | 2822 | 0.400 |
Why?
|
| Anticonvulsants | 7 | 2016 | 1921 | 0.390 |
Why?
|
| Piperazines | 8 | 2012 | 2549 | 0.390 |
Why?
|
| Benzamides | 8 | 2012 | 1377 | 0.380 |
Why?
|
| Young Adult | 45 | 2025 | 59889 | 0.380 |
Why?
|
| Anilides | 4 | 2018 | 415 | 0.380 |
Why?
|
| T-Lymphocytes | 11 | 2024 | 10261 | 0.380 |
Why?
|
| Mutation | 28 | 2025 | 30198 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2020 | 10729 | 0.380 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2022 | 1880 | 0.370 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 735 | 0.370 |
Why?
|
| Follow-Up Studies | 34 | 2025 | 39193 | 0.370 |
Why?
|
| Sulfonamides | 3 | 2013 | 1984 | 0.360 |
Why?
|
| Fibronectins | 1 | 2014 | 719 | 0.360 |
Why?
|
| Tissue Distribution | 9 | 2019 | 2266 | 0.360 |
Why?
|
| Nervous System Diseases | 2 | 2021 | 1660 | 0.350 |
Why?
|
| Striae Distensae | 1 | 2010 | 7 | 0.350 |
Why?
|
| Rare Diseases | 1 | 2016 | 635 | 0.340 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2010 | 117 | 0.330 |
Why?
|
| Medulloblastoma | 5 | 2008 | 658 | 0.330 |
Why?
|
| Tumor Burden | 9 | 2018 | 1885 | 0.330 |
Why?
|
| Cerebellar Neoplasms | 5 | 2015 | 571 | 0.320 |
Why?
|
| Animals | 50 | 2024 | 168764 | 0.320 |
Why?
|
| Carmustine | 7 | 2014 | 137 | 0.310 |
Why?
|
| Kynurenine | 2 | 2020 | 142 | 0.310 |
Why?
|
| Positron-Emission Tomography | 11 | 2024 | 6547 | 0.310 |
Why?
|
| Ulcer | 1 | 2010 | 201 | 0.310 |
Why?
|
| Lymphopenia | 4 | 2012 | 297 | 0.310 |
Why?
|
| Immunologic Factors | 3 | 2022 | 1587 | 0.300 |
Why?
|
| Craniopharyngioma | 2 | 2023 | 276 | 0.300 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2021 | 1106 | 0.300 |
Why?
|
| DNA Methylation | 9 | 2023 | 4424 | 0.290 |
Why?
|
| Thrombocytopenia | 3 | 2015 | 1171 | 0.290 |
Why?
|
| Health Behavior | 3 | 2011 | 2650 | 0.280 |
Why?
|
| Molecular Biology | 1 | 2011 | 574 | 0.280 |
Why?
|
| Exercise | 4 | 2011 | 5937 | 0.280 |
Why?
|
| Retrospective Studies | 47 | 2025 | 81514 | 0.270 |
Why?
|
| Exotoxins | 5 | 2008 | 123 | 0.270 |
Why?
|
| Peptides, Cyclic | 1 | 2008 | 390 | 0.260 |
Why?
|
| Phthalazines | 1 | 2009 | 397 | 0.260 |
Why?
|
| Interferon-gamma | 4 | 2023 | 3160 | 0.260 |
Why?
|
| Recurrence | 10 | 2015 | 8501 | 0.260 |
Why?
|
| Neoplasm Staging | 18 | 2019 | 11206 | 0.260 |
Why?
|
| Psychological Theory | 1 | 2007 | 172 | 0.250 |
Why?
|
| Pyrroles | 2 | 2011 | 1119 | 0.250 |
Why?
|
| Aged, 80 and over | 32 | 2022 | 59489 | 0.250 |
Why?
|
| Chromosome Aberrations | 4 | 2019 | 1774 | 0.250 |
Why?
|
| Mice | 29 | 2024 | 81819 | 0.240 |
Why?
|
| Thalamus | 2 | 2004 | 1048 | 0.240 |
Why?
|
| Guanine | 6 | 2009 | 282 | 0.240 |
Why?
|
| Kluver-Bucy Syndrome | 1 | 2004 | 9 | 0.230 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2009 | 616 | 0.230 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2015 | 639 | 0.230 |
Why?
|
| Rhabdoid Tumor | 2 | 2017 | 209 | 0.220 |
Why?
|
| Contrast Media | 6 | 2019 | 5329 | 0.220 |
Why?
|
| Intention | 1 | 2007 | 346 | 0.220 |
Why?
|
| Holography | 1 | 2024 | 80 | 0.220 |
Why?
|
| Blood Vessels | 2 | 2008 | 1113 | 0.220 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2000 | 1306 | 0.220 |
Why?
|
| Cell Line, Tumor | 14 | 2020 | 17075 | 0.210 |
Why?
|
| Tuberous Sclerosis | 1 | 2011 | 1038 | 0.210 |
Why?
|
| Respiration | 1 | 2010 | 1653 | 0.210 |
Why?
|
| STAT Transcription Factors | 1 | 2023 | 189 | 0.210 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 4 | 2013 | 82 | 0.210 |
Why?
|
| Medulla Oblongata | 1 | 2004 | 246 | 0.210 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2023 | 64 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 7 | 2021 | 5786 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 2895 | 0.200 |
Why?
|
| Janus Kinases | 1 | 2023 | 253 | 0.200 |
Why?
|
| Karnofsky Performance Status | 5 | 2019 | 163 | 0.200 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2022 | 43 | 0.200 |
Why?
|
| Drug Therapy, Combination | 5 | 2017 | 6309 | 0.200 |
Why?
|
| Drug Interactions | 2 | 2020 | 1417 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2024 | 878 | 0.200 |
Why?
|
| Peptide Fragments | 1 | 2014 | 5125 | 0.190 |
Why?
|
| Vaccination | 3 | 2021 | 3426 | 0.190 |
Why?
|
| Signal Transduction | 12 | 2023 | 23601 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 2047 | 0.190 |
Why?
|
| Enzyme Inhibitors | 5 | 2012 | 3715 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 2570 | 0.190 |
Why?
|
| Transforming Growth Factor alpha | 3 | 2008 | 134 | 0.190 |
Why?
|
| Phosphoramide Mustards | 1 | 2021 | 18 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 7425 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2020 | 3737 | 0.180 |
Why?
|
| Ki-67 Antigen | 2 | 2022 | 629 | 0.180 |
Why?
|
| Administration, Oral | 5 | 2011 | 4015 | 0.180 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2021 | 85 | 0.180 |
Why?
|
| Cohort Studies | 19 | 2024 | 41649 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2020 | 640 | 0.180 |
Why?
|
| Interleukin-12 | 2 | 2022 | 579 | 0.180 |
Why?
|
| Chromosome Deletion | 3 | 2020 | 1385 | 0.170 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 305 | 0.170 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2018 | 3672 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 3602 | 0.170 |
Why?
|
| Nitroimidazoles | 1 | 2021 | 117 | 0.170 |
Why?
|
| Adenoma | 2 | 2023 | 2152 | 0.170 |
Why?
|
| Gliosarcoma | 1 | 2020 | 116 | 0.160 |
Why?
|
| Random Allocation | 2 | 2023 | 2395 | 0.160 |
Why?
|
| Giant Cells | 1 | 2000 | 187 | 0.160 |
Why?
|
| Fatigue | 4 | 2016 | 1549 | 0.160 |
Why?
|
| Purpura | 1 | 2020 | 115 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2021 | 5337 | 0.160 |
Why?
|
| DNA Mutational Analysis | 7 | 2021 | 4108 | 0.160 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 18293 | 0.160 |
Why?
|
| Rats, Inbred F344 | 1 | 2020 | 822 | 0.160 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2020 | 239 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 350 | 0.160 |
Why?
|
| Genes, myc | 1 | 2000 | 393 | 0.150 |
Why?
|
| Maytansine | 1 | 2019 | 87 | 0.150 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2024 | 456 | 0.150 |
Why?
|
| Adipose Tissue, Brown | 1 | 2024 | 776 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2019 | 124 | 0.150 |
Why?
|
| Tryptophan | 1 | 2020 | 483 | 0.150 |
Why?
|
| Gyrus Cinguli | 1 | 2004 | 1117 | 0.150 |
Why?
|
| Prodrugs | 1 | 2020 | 273 | 0.150 |
Why?
|
| Astatine | 2 | 2007 | 10 | 0.150 |
Why?
|
| Algorithms | 9 | 2020 | 14071 | 0.140 |
Why?
|
| Adolescent | 29 | 2025 | 88835 | 0.140 |
Why?
|
| Pyridazines | 1 | 2019 | 200 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1999 | 371 | 0.140 |
Why?
|
| Decanoic Acids | 2 | 2009 | 68 | 0.140 |
Why?
|
| Protein Phosphatase 1 | 1 | 2018 | 135 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1998 | 311 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2011 | 1333 | 0.140 |
Why?
|
| Ependymoma | 2 | 2005 | 310 | 0.140 |
Why?
|
| Pyrazoles | 2 | 2023 | 2033 | 0.140 |
Why?
|
| Pilot Projects | 6 | 2020 | 8733 | 0.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2023 | 2054 | 0.140 |
Why?
|
| Neurosurgical Procedures | 5 | 2019 | 2074 | 0.140 |
Why?
|
| Area Under Curve | 5 | 2016 | 1638 | 0.130 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2019 | 222 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2020 | 10383 | 0.130 |
Why?
|
| Heart | 1 | 2010 | 4414 | 0.130 |
Why?
|
| Glutarates | 1 | 2018 | 243 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2023 | 790 | 0.130 |
Why?
|
| Cranial Irradiation | 1 | 2019 | 385 | 0.130 |
Why?
|
| Apyrase | 1 | 2019 | 373 | 0.130 |
Why?
|
| Amygdala | 1 | 2004 | 1377 | 0.130 |
Why?
|
| Injections, Intralesional | 2 | 2008 | 281 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2021 | 8923 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2020 | 1801 | 0.130 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2015 | 17 | 0.130 |
Why?
|
| Gadolinium DTPA | 2 | 2011 | 823 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2015 | 3111 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2024 | 2475 | 0.130 |
Why?
|
| Rats | 3 | 2024 | 23707 | 0.130 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 1009 | 0.130 |
Why?
|
| Antigens, Viral | 1 | 2020 | 995 | 0.130 |
Why?
|
| Morpholines | 1 | 2019 | 577 | 0.130 |
Why?
|
| Consensus | 5 | 2025 | 3202 | 0.130 |
Why?
|
| Polyesters | 2 | 2009 | 372 | 0.120 |
Why?
|
| Portraits as Topic | 1 | 2015 | 33 | 0.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2015 | 330 | 0.120 |
Why?
|
| Ganglioglioma | 1 | 2015 | 36 | 0.120 |
Why?
|
| Piracetam | 1 | 2016 | 88 | 0.120 |
Why?
|
| Tissue Extracts | 1 | 2015 | 139 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2024 | 8611 | 0.120 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 84 | 0.120 |
Why?
|
| Proportional Hazards Models | 11 | 2023 | 12509 | 0.120 |
Why?
|
| Immunotoxins | 4 | 2008 | 177 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2018 | 429 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 1998 | 2505 | 0.120 |
Why?
|
| Lymphoma | 3 | 2013 | 1897 | 0.120 |
Why?
|
| Aminopyridines | 1 | 2019 | 576 | 0.120 |
Why?
|
| Epilepsy | 2 | 2024 | 3320 | 0.120 |
Why?
|
| Biological Transport | 1 | 2019 | 2081 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2020 | 618 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2020 | 3608 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 6069 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 4958 | 0.120 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2016 | 149 | 0.120 |
Why?
|
| Infratentorial Neoplasms | 1 | 2015 | 94 | 0.120 |
Why?
|
| Gene Expression | 2 | 2018 | 7584 | 0.120 |
Why?
|
| Tetanus Toxoid | 1 | 2015 | 188 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2020 | 962 | 0.120 |
Why?
|
| Central Nervous System | 1 | 2022 | 1341 | 0.120 |
Why?
|
| Immunohistochemistry | 9 | 2018 | 11022 | 0.110 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2018 | 268 | 0.110 |
Why?
|
| Brachytherapy | 2 | 2015 | 1222 | 0.110 |
Why?
|
| Tyrosine | 1 | 2018 | 1428 | 0.110 |
Why?
|
| Gene Amplification | 1 | 2019 | 1091 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2014 | 136 | 0.110 |
Why?
|
| Radiopharmaceuticals | 7 | 2010 | 2699 | 0.110 |
Why?
|
| Patient Selection | 4 | 2020 | 4255 | 0.110 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 805 | 0.110 |
Why?
|
| Prospective Studies | 13 | 2025 | 54802 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 1994 | 119 | 0.110 |
Why?
|
| Diagnostic Imaging | 4 | 2014 | 3529 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2013 | 754 | 0.110 |
Why?
|
| World Health Organization | 4 | 2022 | 1328 | 0.110 |
Why?
|
| DNA, Neoplasm | 2 | 2004 | 1742 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 728 | 0.110 |
Why?
|
| Chromosome Mapping | 3 | 1998 | 4618 | 0.110 |
Why?
|
| Imidazoles | 1 | 2019 | 1162 | 0.110 |
Why?
|
| Receptors, Cell Surface | 3 | 2021 | 2817 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2017 | 962 | 0.110 |
Why?
|
| Patients | 1 | 2020 | 910 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2024 | 8102 | 0.110 |
Why?
|
| Double-Blind Method | 4 | 2020 | 12437 | 0.100 |
Why?
|
| Mibefradil | 1 | 2012 | 5 | 0.100 |
Why?
|
| Valproic Acid | 1 | 2016 | 445 | 0.100 |
Why?
|
| Skin Neoplasms | 3 | 2018 | 5849 | 0.100 |
Why?
|
| Treatment Failure | 4 | 2017 | 2652 | 0.100 |
Why?
|
| Time Factors | 13 | 2019 | 40065 | 0.100 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3454 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2018 | 1329 | 0.100 |
Why?
|
| Somatostatin | 1 | 2014 | 459 | 0.100 |
Why?
|
| Benzenesulfonates | 2 | 2010 | 170 | 0.100 |
Why?
|
| Attitude to Health | 2 | 2019 | 2020 | 0.100 |
Why?
|
| Teratoma | 1 | 2015 | 401 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2019 | 3537 | 0.100 |
Why?
|
| Confidence Intervals | 3 | 2014 | 2910 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 483 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 4642 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 561 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2018 | 1470 | 0.100 |
Why?
|
| Immunity | 2 | 2015 | 1002 | 0.100 |
Why?
|
| Cell Movement | 4 | 2018 | 5194 | 0.090 |
Why?
|
| Endpoint Determination | 1 | 2014 | 591 | 0.090 |
Why?
|
| Quality of Life | 6 | 2019 | 13462 | 0.090 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2008 | 1426 | 0.090 |
Why?
|
| Interleukin-13 | 3 | 2010 | 388 | 0.090 |
Why?
|
| Niacinamide | 2 | 2010 | 419 | 0.090 |
Why?
|
| Indazoles | 1 | 2013 | 303 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 1514 | 0.090 |
Why?
|
| Antineoplastic Protocols | 1 | 2011 | 47 | 0.090 |
Why?
|
| Tablets | 1 | 2011 | 149 | 0.090 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1991 | 24 | 0.090 |
Why?
|
| Optic Nerve Glioma | 1 | 2011 | 32 | 0.090 |
Why?
|
| Cell Survival | 2 | 2018 | 5747 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 2176 | 0.090 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2011 | 49 | 0.090 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2011 | 45 | 0.090 |
Why?
|
| Yin-Yang | 1 | 2010 | 10 | 0.090 |
Why?
|
| Research Design | 4 | 2022 | 6209 | 0.090 |
Why?
|
| Neutropenia | 2 | 2015 | 893 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2006 | 258 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 1998 | 1242 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 1991 | 97 | 0.090 |
Why?
|
| Telomerase | 1 | 2015 | 749 | 0.090 |
Why?
|
| Child, Preschool | 19 | 2024 | 42500 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2025 | 24282 | 0.080 |
Why?
|
| Probability | 2 | 2006 | 2475 | 0.080 |
Why?
|
| Piperidines | 2 | 2011 | 1664 | 0.080 |
Why?
|
| Phenylurea Compounds | 2 | 2010 | 536 | 0.080 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2016 | 476 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2329 | 0.080 |
Why?
|
| DNA Copy Number Variations | 2 | 2015 | 2045 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2015 | 1574 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 634 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 605 | 0.080 |
Why?
|
| Calcium Channel Blockers | 1 | 2012 | 686 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 1490 | 0.080 |
Why?
|
| Diarrhea | 2 | 2015 | 1316 | 0.080 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 939 | 0.080 |
Why?
|
| Brain | 10 | 2021 | 27171 | 0.080 |
Why?
|
| Child | 21 | 2025 | 80564 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1994 | 689 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2018 | 2589 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2022 | 3181 | 0.080 |
Why?
|
| Immunologic Memory | 1 | 2015 | 1375 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2019 | 4025 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2018 | 3404 | 0.070 |
Why?
|
| Age Factors | 5 | 2024 | 18380 | 0.070 |
Why?
|
| STAT1 Transcription Factor | 2 | 2020 | 339 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1761 | 0.070 |
Why?
|
| Predictive Value of Tests | 8 | 2020 | 15398 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2018 | 2858 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2009 | 488 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2015 | 2761 | 0.070 |
Why?
|
| Kidney Neoplasms | 2 | 2022 | 4274 | 0.070 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2009 | 345 | 0.070 |
Why?
|
| Drug Design | 1 | 2012 | 1042 | 0.070 |
Why?
|
| Attitude | 1 | 1992 | 770 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 4893 | 0.070 |
Why?
|
| Vestibular Nerve | 1 | 2007 | 101 | 0.070 |
Why?
|
| Radiometry | 3 | 2007 | 804 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 4353 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3615 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 1534 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2878 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2006 | 869 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2024 | 3356 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2022 | 3655 | 0.070 |
Why?
|
| Farnesyltranstransferase | 1 | 2006 | 70 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3278 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2012 | 5302 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2019 | 5993 | 0.060 |
Why?
|
| Body Burden | 1 | 2006 | 156 | 0.060 |
Why?
|
| Abortion, Induced | 1 | 1992 | 471 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 22332 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 723 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2005 | 2229 | 0.060 |
Why?
|
| Macrophages | 2 | 2019 | 5772 | 0.060 |
Why?
|
| Decision Making | 1 | 2019 | 3965 | 0.060 |
Why?
|
| Cell Lineage | 1 | 2014 | 2573 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4900 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 438 | 0.060 |
Why?
|
| Muscle Strength | 1 | 2010 | 637 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2010 | 742 | 0.060 |
Why?
|
| Biopsy | 3 | 2021 | 6763 | 0.060 |
Why?
|
| Chromosome Disorders | 2 | 1999 | 498 | 0.060 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 20124 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 1991 | 866 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 4270 | 0.060 |
Why?
|
| Cochlear Nerve | 1 | 2007 | 202 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2007 | 704 | 0.060 |
Why?
|
| Receptor, erbB-2 | 2 | 2014 | 2593 | 0.060 |
Why?
|
| Hydrazines | 1 | 2006 | 223 | 0.060 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 1107 | 0.060 |
Why?
|
| Catheterization | 1 | 2010 | 1425 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2006 | 297 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 1560 | 0.060 |
Why?
|
| DNA Helicases | 2 | 2024 | 852 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2015 | 2942 | 0.060 |
Why?
|
| Thiazoles | 1 | 2012 | 1529 | 0.060 |
Why?
|
| Paranoid Disorders | 1 | 2004 | 60 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2011 | 2056 | 0.060 |
Why?
|
| Drug Industry | 1 | 2011 | 791 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2012 | 2920 | 0.060 |
Why?
|
| Neoplasm Proteins | 3 | 2013 | 3596 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1927 | 0.060 |
Why?
|
| Seizures | 3 | 2024 | 3000 | 0.060 |
Why?
|
| Reference Values | 2 | 2014 | 4908 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 4247 | 0.060 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 13451 | 0.060 |
Why?
|
| Biological Availability | 1 | 2005 | 385 | 0.060 |
Why?
|
| Walking | 1 | 2011 | 1198 | 0.060 |
Why?
|
| Lomustine | 2 | 2014 | 60 | 0.060 |
Why?
|
| Infant | 12 | 2018 | 36386 | 0.050 |
Why?
|
| Neurofibromatosis 2 | 1 | 2007 | 387 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 1870 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2007 | 837 | 0.050 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2007 | 388 | 0.050 |
Why?
|
| Transducers | 1 | 2024 | 239 | 0.050 |
Why?
|
| Neuroma, Acoustic | 1 | 2007 | 456 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 1262 | 0.050 |
Why?
|
| Pinealoma | 1 | 2003 | 51 | 0.050 |
Why?
|
| Papilloma, Choroid Plexus | 2 | 1999 | 9 | 0.050 |
Why?
|
| Culture | 1 | 2007 | 622 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 3251 | 0.050 |
Why?
|
| Acoustics | 1 | 2024 | 235 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 1991 | 2729 | 0.050 |
Why?
|
| Injections, Intraventricular | 3 | 2008 | 227 | 0.050 |
Why?
|
| Pineal Gland | 1 | 2003 | 153 | 0.050 |
Why?
|
| Cross-Priming | 1 | 2022 | 75 | 0.050 |
Why?
|
| Demography | 1 | 2007 | 1641 | 0.050 |
Why?
|
| Temporal Muscle | 1 | 2021 | 36 | 0.050 |
Why?
|
| Genes, erbB | 1 | 2001 | 5 | 0.050 |
Why?
|
| Radiosurgery | 1 | 2011 | 1328 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2009 | 6203 | 0.050 |
Why?
|
| Misonidazole | 1 | 2021 | 33 | 0.050 |
Why?
|
| Convection | 2 | 2011 | 30 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2014 | 3595 | 0.050 |
Why?
|
| Losartan | 1 | 2023 | 263 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 12976 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2006 | 2263 | 0.050 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 9525 | 0.040 |
Why?
|
| Pentamidine | 1 | 2020 | 44 | 0.040 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2007 | 781 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 1624 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2010 | 13039 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2023 | 631 | 0.040 |
Why?
|
| Venous Thromboembolism | 2 | 2014 | 1882 | 0.040 |
Why?
|
| Mice, Nude | 3 | 2018 | 3618 | 0.040 |
Why?
|
| Virus Replication | 2 | 2018 | 2447 | 0.040 |
Why?
|
| Body Composition | 1 | 2010 | 2439 | 0.040 |
Why?
|
| Age Distribution | 1 | 2006 | 2858 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2007 | 1424 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2021 | 162 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2001 | 249 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 1701 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 2000 | 772 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 2080 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 2423 | 0.040 |
Why?
|
| Palliative Care | 1 | 2014 | 3645 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2003 | 647 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 2865 | 0.040 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 1999 | 38 | 0.040 |
Why?
|
| Drug Approval | 2 | 2018 | 818 | 0.040 |
Why?
|
| Substrate Specificity | 2 | 2015 | 1752 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2844 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 330 | 0.040 |
Why?
|
| Affect | 1 | 2007 | 1500 | 0.040 |
Why?
|
| DNA Probes | 1 | 2000 | 541 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2000 | 313 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 1119 | 0.040 |
Why?
|
| Motor Activity | 1 | 2009 | 2704 | 0.040 |
Why?
|
| Receptor, TIE-2 | 1 | 2019 | 183 | 0.040 |
Why?
|
| Edema | 1 | 2023 | 760 | 0.040 |
Why?
|
| Wound Healing | 1 | 2010 | 2792 | 0.040 |
Why?
|
| Observer Variation | 2 | 2015 | 2615 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 12056 | 0.040 |
Why?
|
| Risk Factors | 5 | 2018 | 74840 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2000 | 416 | 0.040 |
Why?
|
| Craniotomy | 2 | 2015 | 730 | 0.040 |
Why?
|
| Immunization | 1 | 2023 | 1219 | 0.040 |
Why?
|
| Vincristine | 3 | 2013 | 1039 | 0.040 |
Why?
|
| Propensity Score | 2 | 2017 | 1968 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2008 | 5379 | 0.040 |
Why?
|
| Hybrid Cells | 1 | 1998 | 421 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 240 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1994 | 3646 | 0.040 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2018 | 147 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2003 | 1648 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1999 | 348 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2021 | 371 | 0.040 |
Why?
|
| Gene Order | 1 | 2018 | 164 | 0.040 |
Why?
|
| Single-Chain Antibodies | 1 | 2018 | 114 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2020 | 784 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 16047 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2005 | 1611 | 0.040 |
Why?
|
| Procarbazine | 2 | 2013 | 172 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 14751 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2022 | 734 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 592 | 0.040 |
Why?
|
| Remission Induction | 1 | 2023 | 2411 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 2210 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 995 | 0.040 |
Why?
|
| Cell Division | 1 | 2005 | 4475 | 0.030 |
Why?
|
| Benzylamines | 1 | 2018 | 251 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2019 | 246 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 245 | 0.030 |
Why?
|
| North Carolina | 2 | 2011 | 329 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1999 | 533 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2009 | 26318 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 562 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 433 | 0.030 |
Why?
|
| Radiotherapy | 2 | 2016 | 1494 | 0.030 |
Why?
|
| Genotype | 3 | 2016 | 13024 | 0.030 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2018 | 175 | 0.030 |
Why?
|
| Software | 2 | 2010 | 4462 | 0.030 |
Why?
|
| Antigens | 1 | 2022 | 1438 | 0.030 |
Why?
|
| Guidelines as Topic | 2 | 2016 | 1394 | 0.030 |
Why?
|
| Hypertension | 2 | 2015 | 8626 | 0.030 |
Why?
|
| Genomics | 2 | 2024 | 5929 | 0.030 |
Why?
|
| Proteins | 1 | 2011 | 5995 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2020 | 651 | 0.030 |
Why?
|
| Interferons | 1 | 2020 | 714 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 1999 | 539 | 0.030 |
Why?
|
| Steroids | 1 | 2021 | 933 | 0.030 |
Why?
|
| Protein Binding | 1 | 2008 | 9296 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 2921 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2020 | 1228 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 1377 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 561 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2015 | 5020 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 1837 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 612 | 0.030 |
Why?
|
| Placebos | 1 | 2020 | 1659 | 0.030 |
Why?
|
| Phenotype | 3 | 2020 | 16721 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 9601 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12807 | 0.030 |
Why?
|
| Nuclear Proteins | 2 | 2024 | 5783 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 4034 | 0.030 |
Why?
|
| X Chromosome | 1 | 1999 | 819 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2000 | 1831 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2354 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 3690 | 0.030 |
Why?
|
| Hospitalization | 1 | 2015 | 10808 | 0.030 |
Why?
|
| Awareness | 1 | 2019 | 653 | 0.030 |
Why?
|
| Leukopenia | 1 | 2015 | 213 | 0.030 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 14652 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 1624 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 870 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2015 | 153 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 1602 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 1995 | 114 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 412 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 4 | 2009 | 6113 | 0.030 |
Why?
|
| Life Style | 1 | 2006 | 3926 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 508 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 244 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2016 | 12768 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2024 | 2921 | 0.030 |
Why?
|
| Immunization, Passive | 2 | 2008 | 616 | 0.030 |
Why?
|
| Pons | 1 | 2015 | 238 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 415 | 0.030 |
Why?
|
| Disease Management | 1 | 2025 | 2535 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4562 | 0.030 |
Why?
|
| Epitopes | 2 | 2018 | 2523 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2001 | 1083 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 598 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2018 | 2476 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2887 | 0.030 |
Why?
|
| Antibodies | 1 | 2002 | 2417 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2014 | 138 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 192 | 0.030 |
Why?
|
| Health Status | 1 | 2007 | 4080 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2001 | 1728 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 3475 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 347 | 0.030 |
Why?
|
| Safety | 1 | 2018 | 1157 | 0.030 |
Why?
|
| Travel | 1 | 2019 | 806 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 2798 | 0.030 |
Why?
|
| Drug Antagonism | 1 | 2013 | 50 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 361 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 9550 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2020 | 3624 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2019 | 3586 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 607 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2022 | 2324 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 1811 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2001 | 5753 | 0.030 |
Why?
|
| Nausea | 1 | 2015 | 680 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2024 | 3430 | 0.030 |
Why?
|
| Microglia | 1 | 2021 | 1372 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 567 | 0.020 |
Why?
|
| Abortion Applicants | 1 | 1992 | 5 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2015 | 912 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2018 | 8278 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2020 | 4772 | 0.020 |
Why?
|
| Exercise Test | 2 | 2011 | 2180 | 0.020 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 2011 | 37 | 0.020 |
Why?
|
| Breast Neoplasms | 4 | 2013 | 21056 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 4348 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 1994 | 430 | 0.020 |
Why?
|
| Educational Status | 1 | 2019 | 2513 | 0.020 |
Why?
|
| Blood Component Transfusion | 1 | 1992 | 138 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 904 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 950 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1275 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2016 | 1216 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 2003 | 2228 | 0.020 |
Why?
|
| Y Chromosome | 1 | 1992 | 205 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2018 | 1365 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3423 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 4405 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2000 | 7851 | 0.020 |
Why?
|
| Constipation | 1 | 2015 | 568 | 0.020 |
Why?
|
| Optic Chiasm | 1 | 2011 | 88 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2024 | 12131 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2010 | 116 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2024 | 6255 | 0.020 |
Why?
|
| Methods | 1 | 2011 | 1052 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 1352 | 0.020 |
Why?
|
| ROC Curve | 1 | 2018 | 3620 | 0.020 |
Why?
|
| Melphalan | 2 | 2003 | 425 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 647 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 720 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 722 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 1383 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1446 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1510 | 0.020 |
Why?
|
| Pregnancy in Adolescence | 1 | 1992 | 164 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2021 | 2517 | 0.020 |
Why?
|
| Scotoma | 1 | 2011 | 128 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 4528 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 777 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2010 | 2024 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1999 | 2844 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2010 | 490 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2010 | 161 | 0.020 |
Why?
|
| Carcinoma | 1 | 2001 | 2312 | 0.020 |
Why?
|
| Epidermal Growth Factor | 2 | 2003 | 698 | 0.020 |
Why?
|
| United States | 4 | 2018 | 72903 | 0.020 |
Why?
|
| Cognition | 1 | 2007 | 7049 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2535 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 3213 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 691 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2015 | 2601 | 0.020 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 6942 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2015 | 1505 | 0.020 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1991 | 230 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 284 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 2014 | 0.020 |
Why?
|
| Base Sequence | 3 | 1995 | 12403 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2011 | 1006 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2023 | 5089 | 0.020 |
Why?
|
| Visual Field Tests | 1 | 2011 | 415 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1884 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2008 | 108 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 1991 | 390 | 0.020 |
Why?
|
| Carotenoids | 1 | 2011 | 619 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2011 | 538 | 0.020 |
Why?
|
| Transcobalamins | 1 | 2007 | 22 | 0.020 |
Why?
|
| Platelet Count | 1 | 1990 | 782 | 0.020 |
Why?
|
| Alpha Particles | 1 | 2007 | 29 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2013 | 839 | 0.020 |
Why?
|
| Cerebellum | 1 | 2015 | 1518 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2018 | 10429 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15747 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2015 | 1714 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 3819 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 845 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2453 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1995 | 17594 | 0.020 |
Why?
|
| Genome, Human | 1 | 2020 | 4448 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 1936 | 0.020 |
Why?
|
| Vitamin E | 1 | 2011 | 869 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7838 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2007 | 218 | 0.020 |
Why?
|
| Vaccines, DNA | 1 | 2008 | 279 | 0.020 |
Why?
|
| Thymidine | 1 | 2006 | 294 | 0.020 |
Why?
|
| Immune System | 1 | 2012 | 799 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 1990 | 557 | 0.020 |
Why?
|
| Stroke | 1 | 2008 | 9747 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2005 | 1276 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2007 | 324 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2007 | 389 | 0.020 |
Why?
|
| Radioisotopes | 1 | 2007 | 495 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2015 | 2446 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2006 | 340 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 1999 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 2077 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 18071 | 0.010 |
Why?
|
| Computational Biology | 1 | 2016 | 3559 | 0.010 |
Why?
|
| Skin | 1 | 2018 | 4489 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2004 | 152 | 0.010 |
Why?
|
| Cytokines | 1 | 2019 | 7421 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 474 | 0.010 |
Why?
|
| Leukocytes | 1 | 1992 | 2027 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2020 | 8067 | 0.010 |
Why?
|
| Visual Fields | 1 | 2011 | 1063 | 0.010 |
Why?
|
| Models, Biological | 2 | 2013 | 9443 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 479 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1991 | 1789 | 0.010 |
Why?
|
| Gangliosides | 1 | 2004 | 132 | 0.010 |
Why?
|
| Counseling | 1 | 1992 | 1551 | 0.010 |
Why?
|
| Fluorine Radioisotopes | 1 | 2006 | 397 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3413 | 0.010 |
Why?
|
| Vision Disorders | 1 | 2011 | 1087 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 1478 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2005 | 437 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 2007 | 768 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2003 | 395 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3807 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 663 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2019 | 3785 | 0.010 |
Why?
|
| Incidence | 2 | 2015 | 21480 | 0.010 |
Why?
|
| Doxorubicin | 2 | 2001 | 2230 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 1145 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2007 | 1072 | 0.010 |
Why?
|
| Corpus Callosum | 1 | 2007 | 751 | 0.010 |
Why?
|
| Nitrosourea Compounds | 1 | 2002 | 32 | 0.010 |
Why?
|
| Necrosis | 1 | 2007 | 1617 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2018 | 4862 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2004 | 1061 | 0.010 |
Why?
|
| Busulfan | 1 | 2003 | 264 | 0.010 |
Why?
|
| Reoperation | 2 | 2005 | 4294 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 6919 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 1886 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 11888 | 0.010 |
Why?
|
| Tyrphostins | 1 | 2001 | 63 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2010 | 2132 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2006 | 1107 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2007 | 2243 | 0.010 |
Why?
|
| Drug Resistance, Viral | 1 | 2005 | 866 | 0.010 |
Why?
|
| Autocrine Communication | 1 | 2001 | 167 | 0.010 |
Why?
|
| Neuregulin-1 | 1 | 2001 | 140 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 1657 | 0.010 |
Why?
|
| Receptor, erbB-3 | 1 | 2001 | 141 | 0.010 |
Why?
|
| Benzothiazoles | 1 | 2001 | 246 | 0.010 |
Why?
|
| Life Tables | 1 | 2000 | 363 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 3236 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 3067 | 0.010 |
Why?
|
| Pedigree | 1 | 2007 | 4526 | 0.010 |
Why?
|
| Colon | 1 | 2007 | 1795 | 0.010 |
Why?
|
| Astrocytes | 1 | 2007 | 1345 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 4209 | 0.010 |
Why?
|
| Growth Substances | 1 | 2001 | 758 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 2004 | 933 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 6274 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1998 | 129 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 2120 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 2567 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 1991 | 3078 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 26346 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 633 | 0.010 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 1999 | 186 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2011 | 2932 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 1999 | 295 | 0.010 |
Why?
|
| DNA Replication | 1 | 2005 | 1433 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1999 | 566 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2007 | 2674 | 0.010 |
Why?
|
| Bleomycin | 1 | 1998 | 491 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 1600 | 0.010 |
Why?
|
| Vinblastine | 1 | 1998 | 483 | 0.010 |
Why?
|
| Choroid Plexus | 1 | 1999 | 250 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 2394 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 6493 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 2372 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1992 | 4533 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 18973 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2000 | 963 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2009 | 2598 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2000 | 1202 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2001 | 712 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5444 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 1995 | 206 | 0.010 |
Why?
|
| Cisplatin | 1 | 2001 | 1658 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 5389 | 0.010 |
Why?
|
| Prednisone | 1 | 1998 | 1565 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 2163 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 7599 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 4392 | 0.010 |
Why?
|
| Glycosylation | 1 | 1995 | 1100 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 705 | 0.010 |
Why?
|
| Blood Donors | 1 | 1992 | 342 | 0.010 |
Why?
|
| Graft Survival | 1 | 2001 | 3890 | 0.010 |
Why?
|
| Pregnancy | 1 | 1992 | 30260 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 20659 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 13400 | 0.000 |
Why?
|
| Liver Transplantation | 1 | 1992 | 2412 | 0.000 |
Why?
|
| DNA | 1 | 1992 | 7202 | 0.000 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1992 | 3675 | 0.000 |
Why?
|